Every Form 4 that Anixa Biosciences, Inc. (ANIX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANIX filings page.
Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased additional Common Stock in the company. On September 10, 2026, he bought 3,000 shares in an open-market or private transaction at $2.75 per share, bringing his directly held stake to 665,000 shares. No Rule 10b5-1 trading plan is reported for this transaction.
Anixa Biosciences Inc (ANIX) director Lewis H. Titterton Jr. reported purchasing 10,000 shares of common stock on September 10, 2026 in an open-market or private transaction at $2.73 per share. Following this purchase, he directly holds 996,967 shares of Anixa Biosciences common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Anixa Biosciences Inc (ANIX) director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on September 10, 2026 at $2.76 per share in an open-market or private transaction. Following this purchase, he directly owns 662,000 shares of Anixa common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock in an open-market transaction on July 31, 2026, at $3.47 per share. After this purchase, he directly holds 657,000 shares of Anixa Biosciences common stock.
Arnold M. Baskies, a director of Anixa Biosciences Inc, exercised employee stock options covering 6,000 shares of common stock on July 27, 2026 at an exercise price of $3.1300 per share. These options were granted on August 23, 2013 and were approaching expiration on August 23, 2026.
To cover the option exercise cost, 5,428 shares of common stock were withheld by Anixa Biosciences Inc at $3.4600 per share. Following this exercise, the related stock option position reported for this grant was reduced to 0 derivative securities.
Amit Kumar, Chief Executive Officer and director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 27, 2026 in a transaction reported as a purchase in open market or private transaction at $3.44 per share, bringing his directly held stake to 652,000 shares.
Anixa Biosciences Inc reported that Chief Executive Officer Amit Kumar purchased 3,188 shares of Common Stock on July 27, 2026, at $3.37 per share in a purchase in open market or private transaction. Following this transaction, he directly holds 647,000 shares.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 3,000 shares of Common Stock on July 24, 2026 at $3.73 per share in an open-market or private transaction. Following this trade, his directly held position increased to 643,812 shares of Anixa Biosciences Inc common stock.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar purchased 5,000 shares of common stock on 2026-07-20 at $3.46 per share in an open-market or private transaction. Following this buy, he directly owns 640,812 shares. The transaction was not marked as pursuant to a Rule 10b5-1 trading plan.
Lewis H. Titterton Jr., a director of Anixa Biosciences Inc, purchased 12,000 shares of common stock on July 20, 2026 at $3.47 per share in a transaction classified as a purchase in open market or private transaction, bringing his direct holdings to 986,967 shares.
Lewis H. Titterton Jr., a director of Anixa Biosciences Inc (ANIX), reported an open-market purchase of 2,797 shares of common stock on July 15, 2026 at $3.28 per share. After this transaction, he directly holds 974,967 shares of Anixa common stock.
Anixa Biosciences Inc director and Chief Executive Officer Amit Kumar reported an open-market purchase of 5,000 shares of Common Stock on July 10, 2026 at $3.04 per share. Following this transaction, he directly holds a total of 635,812 shares of Anixa Biosciences common stock.
Anixa Biosciences director Lewis H. Titterton Jr. bought 2,836 shares of Anixa Biosciences common stock in an open-market purchase at $2.64 per share. After this transaction, he directly holds 972,170 common shares, indicating a small incremental increase in his personal stake in the company.
Anixa Biosciences Chief Executive Officer Amit Kumar reported an open-market purchase of 21,000 shares of Common Stock at $2.50 per share. This transaction increased his direct ownership to 630,812 shares following the trade. The filing reflects a single buy transaction with no accompanying sales or derivative exercises.
Anixa Biosciences director Arnold M. Baskies reported buying additional company stock. On January 28, 2026, he purchased 10,000 shares of Anixa Biosciences common stock at $3.04 per share. Following this open-market purchase, he directly owns 135,000 shares of the company’s common stock.
Anixa Biosciences director Lewis H. Titterton Jr. filed a Form 4 reporting a grant of employee stock options. On January 5, 2026, he received options to purchase 25,000 shares of Anixa Biosciences common stock at an exercise price of $3.18 per share under the company’s 2018 Share Incentive Plan.
The options vest and become exercisable in twelve equal monthly installments beginning January 31, 2026, and are scheduled to expire on January 5, 2036. Following this grant, Titterton directly holds 25,000 derivative securities (stock options) related to Anixa common stock.
Anixa Biosciences Inc executive Michael J. Catelani, who serves as President, COO and CFO, reported a new stock option grant. On January 5, 2026, he received an employee stock option giving him the right to buy 175,000 shares of Anixa common stock at an exercise price of $3.18 per share under the company’s 2018 Share Incentive Plan. The filing states that these options were granted at no cost to him as a derivative security and are held directly.
The options vest in thirty-six equal monthly installments beginning on January 31, 2026, meaning portions of the grant become exercisable each month over a three-year period. After this grant, Catelani beneficially owns 175,000 stock options, all reported as directly owned.
Anixa Biosciences director Arnold M. Baskies received a grant of employee stock options for 25,000 shares of common stock on January 5, 2026. The options have an exercise price of $3.18 per share and were granted as a Right-To-Buy under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. They vest in twelve equal monthly installments beginning January 31, 2026 and expire on January 5, 2036. Following this award, Baskies holds 25,000 derivative securities directly in the form of these options, which had no purchase price at grant.
Anixa Biosciences Inc director Lewis H. Titterton, Jr. reported an insider stock transaction. On 12/15/2025, he exercised an employee stock option granted on 02/18/2016 with an exercise price of $2.92 per share, acquiring 16,000 shares of Anixa Biosciences common stock through a transaction coded "M" (option exercise).
Following this transaction, Titterton directly beneficially owned 969,334 shares of Anixa Biosciences common stock. The option covered 16,000 underlying shares, and after the exercise the number of derivative securities reported for this option position was 0.
Anixa Biosciences (ANIX) CEO Amit Kumar reported an insider option exercise. On 10/30/2025, he exercised 200,000 stock options at $2.92 per share (code M), adding common shares.
To cover the exercise price and tax withholding, 169,439 shares were withheld and reported as a disposition at $4.06 (code F). Following these transactions, Kumar beneficially owns 610,486 shares directly. The filing notes no open-market share sales in connection with this exercise.